PharmaTimes

FDA approves Tivicay pd for youngest HIV patients

John Pinching — Thu, 03 Sep 2026 09:50:00 +0000

New treatment option expands paediatric HIV care access

Connected trials

John Pinching — Thu, 03 Sep 2026 07:59:00 +0000

Clinical trials are becoming increasingly complex. In a 2023 survey, 70% of investigative site staff said conducting studies had become more difficult over the previous five years. For sponsors, this shows up as delayed decisions, duplicated effort and reduced visibility across their studies. The challenge is rarely a lack of information. More often, it stems […]

Koala trial doses first patient with novel KMA‑targeting CAR‑T

John Pinching — Wed, 02 Sep 2026 07:38:50 +0000

Australian teams advance first‑in‑human multiple myeloma therapy

Heparegenix wins orphan drug status for darizmetinib

John Pinching — Wed, 02 Sep 2026 07:31:05 +0000

Designation supports development for post‑hepatectomy liver failure

IMAVVY approved as first targeted therapy for wAIHA

John Pinching — Tue, 01 Sep 2026 10:15:59 +0000

New treatment reduces pathogenic IgG while preserving B‑cell function

Nxera partner gains acceptance for NBI‑1117567

John Pinching — Tue, 01 Sep 2026 10:11:23 +0000

Phase 2 study to assess muscarinic M1 agonist in Alzheimer’s cognition

Jemperli accepted for priority review by US FDA

John Pinching — Mon, 31 Aug 2026 09:59:33 +0000

sBLA covers dMMR/MSI‑H stage II–III rectal cancer

Carterra supports AI‑designed protein study with HT-SPR platforms

John Pinching — Mon, 31 Aug 2026 09:55:25 +0000

Anthropic, twist and Adaptyv validate 1,320 binders across 15 targets

Erasca secures FDA fast track for eras‑0015 in pancreatic cancer

John Pinching — Thu, 27 Aug 2026 09:51:02 +0000

Designation supports rapid development of pan‑RAS molecular glue

Avulux gains FDA authorisation for migraine light‑sensitivity lens

John Pinching — Thu, 27 Aug 2026 09:46:30 +0000

New device classification created for precision optical filter